(Reuters) - The Danbury, Connecticut-based company said in an amended filing with the U.S. Securities and Exchange Commission that Morgan Stanley & Co. Inc., Banc of America Securities LLC, Leerink Swann & Co. Inc., Natexis Bleichroeder Inc. were underwriting the IPO.
The underwriters will have an option to buy an additional 750,000 shares to cover over-allotments, the developer and marketer of treatments for endocrine disorders such as diabetes and osteoporosis said.
Read more at Reuters.com Bonds News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment